Matches in UGent Biblio for { <https://biblio.ugent.be/publication/2034412#aggregation> ?p ?o. }
Showing items 1 to 42 of
42
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B292726.
- aggregation creator B292727.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2011".
- aggregation format "application/pdf".
- aggregation hasFormat 2034412.bibtex.
- aggregation hasFormat 2034412.csv.
- aggregation hasFormat 2034412.dc.
- aggregation hasFormat 2034412.didl.
- aggregation hasFormat 2034412.doc.
- aggregation hasFormat 2034412.json.
- aggregation hasFormat 2034412.mets.
- aggregation hasFormat 2034412.mods.
- aggregation hasFormat 2034412.rdf.
- aggregation hasFormat 2034412.ris.
- aggregation hasFormat 2034412.txt.
- aggregation hasFormat 2034412.xls.
- aggregation hasFormat 2034412.yaml.
- aggregation isPartOf urn:issn:0091-6749.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis".
- aggregation abstract "Background: Approximately 85% of nasal polyps (NPs) in white subjects are characterized by prominent eosinophilia. IL-5 is the key driver of eosinophilic differentiation and survival. Objective: We sought to investigate the therapeutic potential of inhibiting IL-5 with a humanized mAb as treatment for severe nasal polyposis. Methods: Thirty patients with severe nasal polyposis (grade 3 or 4 or recurrent after surgery) refractory to corticosteroid therapy were randomized in a double-blindfashion to receive either 2 single intravenous injections (28 days apart) of 750 mg of mepolizumab (n = 20) or placebo (n = 10). Change from baseline in NP score was assessed monthly until 1 month after the last dose (week 8). Computed tomographic scans were also performed at week 8. Results: Twelve of 20 patients receiving mepolizumab had a significantly improved NP score and computed tomographic scan score compared with 1 of 10 patients receiving placebo at week 8 versus baseline. Conclusion: Mepolizumab achieved a statistically significant reduction in NP size for at least 1 month after dosing in 12 of 20 patients. IL-5 inhibition is a potential novel therapeutic approach in patients with severe eosinophilic nasal polyposis.".
- aggregation authorList BK577706.
- aggregation endPage "995".
- aggregation issue "5".
- aggregation startPage "989".
- aggregation volume "128".
- aggregation aggregates 2063868.
- aggregation isDescribedBy 2034412.
- aggregation similarTo j.jaci.2011.07.056.
- aggregation similarTo LU-2034412.